Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Capeserod - Entero Therapeutics

Drug Profile

Capeserod - Entero Therapeutics

Alternative Names: SL-65.0155; SL-650155

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Entero Therapeutics; sanofi-aventis
  • Class Anti-inflammatories; Antidementias; Urologics
  • Mechanism of Action Serotonin 4 receptor agonists; Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastroparesis; Ulcerative colitis
  • Discontinued Alzheimer's disease; Urinary incontinence

Most Recent Events

  • 16 May 2024 First Wave Biopharma is now called Entero Therapeutics
  • 05 Apr 2024 First Wave Biopharma plans a meeting with the US FDA to establish a development and regulatory pathway for Capeserod in Gastrointestinal disorders with the intent to initiate clinical trials in 2025 (First Wave BioPharma SEC 2024)
  • 18 Dec 2023 First Wave Biopharma plans a phase I trial in Gastroparesis (First Wave Biopharma pipeline, December 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top